PortfoliosLab logoPortfoliosLab logo
BMAR vs. BOUT
Performance
Return for Risk
Dividends
Drawdowns
Volatility

Performance

BMAR vs. BOUT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Innovator U.S. Equity Buffer ETF - March (BMAR) and Innovator IBD Breakout Opportunities ETF (BOUT). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

BMAR vs. BOUT - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
BMAR
Innovator U.S. Equity Buffer ETF - March
-1.06%14.97%16.49%23.09%-7.06%16.79%10.88%
BOUT
Innovator IBD Breakout Opportunities ETF
8.23%-6.77%18.82%13.27%-22.60%22.69%57.16%

Returns By Period

In the year-to-date period, BMAR achieves a -1.06% return, which is significantly lower than BOUT's 8.23% return.


BMAR

1D
2.26%
1M
-3.51%
YTD
-1.06%
6M
1.73%
1Y
15.27%
3Y*
14.84%
5Y*
10.86%
10Y*

BOUT

1D
2.67%
1M
-3.79%
YTD
8.23%
6M
1.15%
1Y
8.69%
3Y*
8.84%
5Y*
4.03%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


BMAR vs. BOUT - Expense Ratio Comparison

BMAR has a 0.79% expense ratio, which is lower than BOUT's 0.80% expense ratio.


Return for Risk

BMAR vs. BOUT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BMAR
BMAR Risk / Return Rank: 7373
Overall Rank
BMAR Sharpe Ratio Rank: 6767
Sharpe Ratio Rank
BMAR Sortino Ratio Rank: 7171
Sortino Ratio Rank
BMAR Omega Ratio Rank: 7979
Omega Ratio Rank
BMAR Calmar Ratio Rank: 6666
Calmar Ratio Rank
BMAR Martin Ratio Rank: 8383
Martin Ratio Rank

BOUT
BOUT Risk / Return Rank: 2525
Overall Rank
BOUT Sharpe Ratio Rank: 2424
Sharpe Ratio Rank
BOUT Sortino Ratio Rank: 2424
Sortino Ratio Rank
BOUT Omega Ratio Rank: 2424
Omega Ratio Rank
BOUT Calmar Ratio Rank: 2828
Calmar Ratio Rank
BOUT Martin Ratio Rank: 2525
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BMAR vs. BOUT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Innovator U.S. Equity Buffer ETF - March (BMAR) and Innovator IBD Breakout Opportunities ETF (BOUT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BMARBOUTDifference

Sharpe ratio

Return per unit of total volatility

1.18

0.40

+0.78

Sortino ratio

Return per unit of downside risk

1.78

0.66

+1.12

Omega ratio

Gain probability vs. loss probability

1.30

1.09

+0.21

Calmar ratio

Return relative to maximum drawdown

1.66

0.65

+1.00

Martin ratio

Return relative to average drawdown

9.38

1.81

+7.57

BMAR vs. BOUT - Sharpe Ratio Comparison

The current BMAR Sharpe Ratio is 1.18, which is higher than the BOUT Sharpe Ratio of 0.40. The chart below compares the historical Sharpe Ratios of BMAR and BOUT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


BMARBOUTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.18

0.40

+0.78

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.96

0.21

+0.76

Sharpe Ratio (All Time)

Calculated using the full available price history

0.85

0.30

+0.55

Correlation

The correlation between BMAR and BOUT is 0.70, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Dividends

BMAR vs. BOUT - Dividend Comparison

BMAR has not paid dividends to shareholders, while BOUT's dividend yield for the trailing twelve months is around 0.32%.


TTM20252024202320222021202020192018
BMAR
Innovator U.S. Equity Buffer ETF - March
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
BOUT
Innovator IBD Breakout Opportunities ETF
0.32%0.34%0.60%1.32%1.35%0.00%0.00%0.00%0.22%

Drawdowns

BMAR vs. BOUT - Drawdown Comparison

The maximum BMAR drawdown since its inception was -21.43%, smaller than the maximum BOUT drawdown of -36.75%. Use the drawdown chart below to compare losses from any high point for BMAR and BOUT.


Loading graphics...

Drawdown Indicators


BMARBOUTDifference

Max Drawdown

Largest peak-to-trough decline

-21.43%

-36.75%

+15.32%

Max Drawdown (1Y)

Largest decline over 1 year

-9.47%

-13.73%

+4.26%

Max Drawdown (5Y)

Largest decline over 5 years

-15.02%

-28.28%

+13.26%

Current Drawdown

Current decline from peak

-3.51%

-6.50%

+2.99%

Average Drawdown

Average peak-to-trough decline

-2.40%

-12.55%

+10.15%

Ulcer Index

Depth and duration of drawdowns from previous peaks

1.67%

4.95%

-3.28%

Volatility

BMAR vs. BOUT - Volatility Comparison

The current volatility for Innovator U.S. Equity Buffer ETF - March (BMAR) is 4.15%, while Innovator IBD Breakout Opportunities ETF (BOUT) has a volatility of 8.61%. This indicates that BMAR experiences smaller price fluctuations and is considered to be less risky than BOUT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


BMARBOUTDifference

Volatility (1M)

Calculated over the trailing 1-month period

4.15%

8.61%

-4.46%

Volatility (6M)

Calculated over the trailing 6-month period

5.88%

17.18%

-11.30%

Volatility (1Y)

Calculated over the trailing 1-year period

12.98%

21.74%

-8.76%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

11.32%

19.54%

-8.22%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

13.81%

22.96%

-9.15%